Back

Inducible non-human primate models of retinal degeneration for testing end stage therapies and understanding disease mechanisms

Ail, D.; Nava, D.; Hwang, I. P.; Brazhnikova, E.; Jaillard, C. N.; Dentel, A.; Joffrois, C.; Rousseau, L.; Degardin, J.; Bertin, S.; Sahel, J. A.; Goureau, O.; Picaud, S.; Dalkara, D.

2022-12-05 bioengineering
10.1101/2022.12.03.518955 bioRxiv
Show abstract

The anatomical differences between the retinas of humans and most animal models pose a challenge for testing novel therapies. Non-human primate (NHP) retina is anatomically closest to the human retina with the presence of a high acuity region called the fovea. However, there is a lack of relevant NHP models for retinal degeneration that can be used for preclinical studies of vision restoration. To address this unmet need we aimed to generate inducible NHP models of photoreceptor degeneration. We generated three cynomolgus macaque models using distinct strategies. We used two genetically targeted strategies using optogenetics and Crispr-Cas9 to ablate specifically rods to mimic rod-cone dystrophy. Additionally, we created an acute model by physical separation of the photoreceptors and retinal pigment epithelium using a polymer patch. Retinal degeneration was evaluated in all three models by in-life exams such as fundus imaging, optical coherence tomography, adaptive optics and electroretinography. In the genetic models we observed punctuate areas of degeneration in the injected area marked by disorganization of outer segments, loss of rod photoreceptors and thinning of the outer nuclear layer. In the acute model, the degeneration was faster and involved both rods and cones. Among the three distinct NHP models, the Crispr-Cas9 based approach was the most advantageous model in view of recapitulating disease specific features and its ease of implementation. The acute model however resulted in the fastest degeneration making it the most relevant model for testing end-stage vision restoration therapies such as stem cell transplantation.

Matching journals

The top 3 journals account for 50% of the predicted probability mass.

1
Experimental Eye Research
30 papers in training set
Top 0.1%
23.2%
2
Investigative Opthalmology & Visual Science
37 papers in training set
Top 0.1%
18.1%
3
Investigative Ophthalmology & Visual Science
22 papers in training set
Top 0.1%
10.4%
50% of probability mass above
4
PLOS ONE
4510 papers in training set
Top 23%
7.4%
5
Scientific Reports
3102 papers in training set
Top 13%
7.0%
6
Translational Vision Science & Technology
35 papers in training set
Top 0.2%
6.6%
7
Ophthalmology Science
20 papers in training set
Top 0.2%
1.7%
8
Frontiers in Medicine
113 papers in training set
Top 4%
1.4%
9
Frontiers in Neuroscience
223 papers in training set
Top 5%
1.3%
10
International Journal of Molecular Sciences
453 papers in training set
Top 14%
0.8%
11
Journal of Biomedical Optics
25 papers in training set
Top 0.6%
0.8%
12
Frontiers in Bioengineering and Biotechnology
88 papers in training set
Top 3%
0.8%
13
iScience
1063 papers in training set
Top 30%
0.8%
14
Clinical and Translational Science
21 papers in training set
Top 1%
0.7%
15
Frontiers in Neurology
91 papers in training set
Top 5%
0.7%
16
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
25 papers in training set
Top 1%
0.7%
17
Biomolecules
95 papers in training set
Top 3%
0.7%
18
Cell Death & Disease
126 papers in training set
Top 3%
0.7%
19
Cell Proliferation
12 papers in training set
Top 0.5%
0.7%
20
Eye
11 papers in training set
Top 0.4%
0.7%
21
Biomedical Optics Express
84 papers in training set
Top 1%
0.7%
22
Molecular Therapy - Methods & Clinical Development
38 papers in training set
Top 0.6%
0.7%
23
Journal of Biophotonics
16 papers in training set
Top 0.7%
0.7%
24
Frontiers in Cellular Neuroscience
79 papers in training set
Top 2%
0.5%